In one paragraphArticle in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Carolyn K McCourtDepartment of Obstetrics & Gynecology, Washington University School of Medicine, St Louis, MO.ORCID 0000-0003-2229-8971 Jacob GrossCenter for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-4245-1155 Victoria WangDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Xiangning BuCenter for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
David PattonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-3855-0166 Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MWASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MUT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4MSidney Kimmel Cancer Center LAPS Institutional CollaborationUG1CA233341 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Steven Cohen, Mitchell Edelson · 2019 to 2026
$3.5MNCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233302NCI NIH HHS UG1 CA233329NCI NIH HHS UG1 CA233339NCI NIH HHS UG1 CA233341
6 · The paper itselfAbstract
purposeNCI-MATCH (EAY131) is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatments. Arm Y evaluated capivasertib, a pan AKT inhibitor, in patients with an
methodsEligible patients had
resultsThe ORR was 28.6% (10 of 35) in the reported primary trial and 36% (9 of 25) in this translational cohort. Mutations in the
conclusionIn patients with
Indexed as
NeoplasmsProto-Oncogene Proteins c-aktPyrimidinesAdultAgedFemaleGenomicsHumansMaleMiddle AgedMutationPyrrolesAKT1 protein, humancapivasertibProto-Oncogene Proteins c-aktPyrimidinesPyrroles
Identifiers
PMID40153687
PMCPMC12085156
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390